证券代码：600276 证券简称：恒瑞医药 公告编号：临 2025-106 江苏恒瑞医药股份有限公司 第九届董事会第十七次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 江苏恒瑞医药股份有限公司（以下简称"公司"）第九届董事会第十七次会 议于 2025 年 7 月 25 日以通讯方式召开。本次会议应到董事 11 人，实到董事 11 人。会议召开符合《公司法》《公司章程》的规定。公司全体董事认真审议并通 过以下议案： 一、《关于收购控股子公司少数股东股权暨关联交易的议案》（详细公告请 见上海证券交易所网站：http://www.sse.com.cn） 赞成：7 票 反对：0 票 弃权：0 票 关联董事孙飘扬先生、戴洪斌先生、张连山先生、孙杰平先生回避表决，其 余 7 名董事参与表决。 本议案已经公司独立董事专门会议审议通过。 二、《关于制定<内部审计管理制度>的议案》（详见上海证券交易所网站： http://www.sse.com.cn） 赞成：11 票 反对：0 票 弃权：0 票 本议案已经公司董事会审计委员会审 ...

恒瑞医药（600276）公告，公司拟以现金4001.44万元收购刘疆、周云曙、蒋素梅、孙绪根、卢正清、 蒋新华、袁开红、陈永江、吴玉霞合计持有的成都盛迪医药有限公司1.4587%股权，其他股东放弃优先 购买权。本次交易完成后，公司将持有成都盛迪97.3866%股权，合并报表范围不会因本次股权收购而 发生变化。 ...

Core Viewpoint - The recent patent granted to Heng Rui Medical for its "Uniform Particle Size Drug-loaded Microspheres" technology marks a significant milestone for Chinese medical device innovation, enabling the company to break into the global market and enhance treatment options for liver cancer patients in China [1][2][5] Group 1: Patent Significance - The patent represents a breakthrough in drug-loaded microsphere technology, allowing for the first time a Chinese company to establish a foothold in the core technology and materials sector of this field [1][2] - This achievement is a key step towards the goal of "high-end medical equipment domestic substitution" as outlined in China's 14th Five-Year Plan [2][5] Group 2: Impact on Liver Cancer Treatment - The technology is expected to significantly reduce the cost and improve the accessibility of D-TACE (Drug-loaded Transarterial Chemoembolization) treatment for liver cancer patients in China, who have been facing high costs associated with imported materials [2][4] - The patent addresses the critical issue of low early diagnosis rates and high recurrence rates in liver cancer treatment, which currently sees a 5-year survival rate of only 12% for late-stage patients [1] Group 3: Technological Advancements - Heng Rui Medical's patented technology achieves a remarkable control of particle size variation (CV value) at below 5%, setting a new global standard for microsphere manufacturing precision [3][4] - The innovation allows for a shift from empirical to personalized precision embolization in D-TACE, laying the groundwork for future integration with other innovative treatment modalities [3] Group 4: Market Dynamics - The patent is expected to disrupt the existing market dominated by foreign companies, which have historically controlled 90% of the drug-loaded microsphere market through patent barriers [4] - With the release of domestic high-quality microsphere production, the company aims to accelerate the process of import substitution and enhance the security of the domestic supply chain [4]

Group 1 - The semi-annual index review results of the Shanghai-Hong Kong Stock Connect AH Share Smart Index were announced by China Securities Index Co., Ltd. and Hang Seng Indexes Company Limited [1] - Heng Rui Medicine (01276.HK) and Hai Tian Wei Ye (03288.HK) will be added to the index [1] - Dongfang Securities (03958.HK) and GAC Group (02238.HK) will be removed from the index [1]

Group 1 - The Shanghai Composite Index decreased by 0.33%, while the Shanghai Elderly Industry Index reported at 7521.21 points [1] - The Shanghai Elderly Industry Index has increased by 8.07% in the past month, 11.86% in the past three months, and 12.60% year-to-date [2] - The index consists of 40 listed companies related to the elderly industry, including health management, leisure tourism, and life insurance, reflecting the overall performance of these companies in the Shanghai market [2] Group 2 - The top ten weighted companies in the Shanghai Elderly Industry Index include: BoRui Pharmaceutical (4.55%), Ecovacs (3.05%), New China Life Insurance (2.83%), China Duty Free Group (2.72%), Tongce Medical (2.64%), Ping An Insurance (2.58%), Nanjing Tourism (2.56%), Huatai Medical (2.51%), China Pacific Insurance (2.51%), and Heng Rui Pharmaceutical (2.5%) [2] - The index is fully composed of companies listed on the Shanghai Stock Exchange, with the following industry distribution: Consumer Discretionary (37.07%), Healthcare (36.05%), Consumer Staples (11.55%), Financials (10.39%), and Communication Services (4.94%) [3] - The index samples are adjusted biannually, with adjustments occurring on the next trading day after the second Friday of June and December [3]

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology industry, expecting the industry index to outperform the market index by over 10% in the next six months [1][40]. Core Insights - The SW pharmaceutical and biotechnology industry outperformed the CSI 300 index, rising by 7.84% from July 11 to July 24, 2025, exceeding the CSI 300's performance by approximately 4.13 percentage points [4][14]. - Most sub-sectors within the industry recorded positive returns during the same period, with the medical research outsourcing and raw materials sectors leading with increases of 14.23% and 9.30%, respectively [4][15]. - Approximately 91% of stocks in the industry achieved positive returns, with notable performers including Borui Pharmaceutical, which saw a weekly increase of 78.98% [16]. Summary by Sections 1. Market Review - The SW pharmaceutical and biotechnology industry outperformed the CSI 300 index, with a rise of 7.84% from July 11 to July 24, 2025, surpassing the CSI 300 by about 4.13 percentage points [14]. - Most sub-sectors recorded positive returns, particularly medical research outsourcing and raw materials, which increased by 14.23% and 9.30%, respectively [15]. - About 91% of stocks in the industry had positive returns, with Borui Pharmaceutical leading at 78.98% [16]. 2. Industry News - The report highlights the ongoing progress of the 11th batch of national drug procurement, with significant updates provided during a government open day event on July 22, 2025 [4][28]. - The announcement of the 11th batch of national drug procurement included a notification for drug information submission, which was highly anticipated [4][28]. 3. Company Announcements - Yekang Pharmaceutical announced that its subsidiary received FDA approval for clinical trials of YKYY029 injection for hypertension treatment [29]. 4. Industry Outlook - The report maintains an "Overweight" rating for the industry, citing a continuous rise in the pharmaceutical and biotechnology sector driven by positive sentiment towards innovative drugs and improved financing data [30]. - The report suggests focusing on investment opportunities within the innovative drug supply chain and highlights several companies across various segments, including medical devices, pharmaceutical commerce, and innovative drugs [30][32].

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology industry, expecting the industry index to outperform the market index by over 10% in the next six months [26][35]. Core Insights - The SW pharmaceutical and biotechnology industry outperformed the CSI 300 index, rising by 7.84% from July 11 to July 24, 2025, exceeding the CSI 300's performance by approximately 4.13 percentage points [9][25]. - Most sub-sectors within the industry recorded positive returns during the same period, with the medical research outsourcing and raw materials sectors leading with increases of 14.23% and 9.30%, respectively [10][25]. - Approximately 91% of stocks in the industry achieved positive returns, with the top performer, Borui Pharmaceutical, seeing a weekly increase of 78.98% [11][25]. - The overall price-to-earnings (PE) ratio for the SW pharmaceutical and biotechnology industry is approximately 52.93 times, which is 4.13 times higher than the CSI 300, indicating a rise in industry valuation [17][25]. Summary by Sections 1. Market Review - The SW pharmaceutical and biotechnology industry outperformed the CSI 300 index, with a rise of 7.84% from July 11 to July 24, 2025 [9]. - Most sub-sectors recorded positive returns, particularly medical research outsourcing and raw materials, which increased by 14.23% and 9.30%, respectively [10]. - About 91% of stocks in the industry achieved positive returns, with Borui Pharmaceutical leading at 78.98% [11]. 2. Industry News - The report highlights significant developments in national drug procurement policies, particularly the announcement of the 11th batch of national drug centralized procurement [23]. - The report also mentions the ongoing efforts in the integration of medical and elderly care services, which are crucial for the industry's long-term growth [22]. 3. Company Announcements - Yutian Pharmaceutical announced that its subsidiary received FDA approval for clinical trials of a new hypertension treatment, indicating potential growth opportunities [24]. 4. Industry Outlook - The report suggests continued investment opportunities in the innovation drug sector, with a focus on companies like Mindray Medical, Yifeng Pharmacy, and Aier Eye Hospital, among others [27].

Market Overview - The FTSE China A50 Index showed a predominantly declining trend with more stocks falling than rising, particularly in the banking, oil, and coal sectors [1][6]. Banking Sector - Everbright Bank had a market capitalization of 241.07 billion with a trading volume of 716 million, closing at 4.08, down by 1.21% [3]. - Major banks like China Ping An, China Pacific Insurance, and China Life Insurance had market capitalizations of 374.58 billion, 360.67 billion, and 1,057.65 billion respectively, with trading volumes of 1.962 billion, 789 million, and 2.959 billion [3]. Oil Sector - China Petroleum and China Sinopec had market capitalizations of 1,586.79 billion and 722.62 billion respectively, with trading volumes of 1.598 billion and 996 million, both showing slight declines [3]. Coal Sector - China Shenhua and Shaanxi Coal had market capitalizations of 763.55 billion and 201.27 billion respectively, with trading volumes of 1.049 billion and 905 million, both experiencing declines [3]. Semiconductor Sector - Northern Huachuang, Cambrian, and Haiguang Information had market capitalizations of 246.76 billion, 281.68 billion, and 328.87 billion respectively, with trading volumes of 5 billion, 2.105 billion, and 8.133 billion, showing positive trends for Cambrian and Haiguang [3]. Alcohol Industry - Kweichow Moutai, Shanxi Fenjiu, and Wuliangye had market capitalizations of 1,827.77 billion, 226.40 billion, and 479.53 billion respectively, with trading volumes of 6.140 billion, 1.609 billion, and 2.285 billion, all showing declines [3]. Electric Power Sector - Changjiang Electric Power had a market capitalization of 191.69 billion with a trading volume of 2.910 billion, showing a slight increase [4]. Securities Sector - CITIC Securities, Ningde Times, and Guotai Junan had market capitalizations of 440.17 billion, 361.23 billion, and 1,289.37 billion respectively, with trading volumes of 3.625 billion, 2.769 billion, and 3.803 billion, with CITIC Securities showing a decline [4]. Consumer Electronics - Industrial Fulian, Luxshare Precision, and Dongfang Fortune had market capitalizations of 569.17 billion, 277.97 billion, and 379.14 billion respectively, with trading volumes of 11.391 billion, 3.082 billion, and 3.138 billion, with mixed performance [4]. Chemical and Pharmaceutical Sector - Heng Rui Pharmaceutical, Muyuan Foods, and SF Holding had market capitalizations of 265.38 billion, 242.76 billion, and 374.34 billion respectively, with trading volumes of 2.874 billion, 1.963 billion, and 1.074 billion, showing varied performance [4].

Policy Developments - The National Healthcare Security Administration (NHSA) has initiated the 11th batch of centralized procurement, optimizing the selection rules by no longer solely relying on the lowest bid as a reference. Companies with the lowest bids must now justify the reasonableness of their pricing and ensure it does not fall below cost [2] Drug and Medical Device Approvals - Senxuan Pharmaceutical's subsidiary has received approval for the market launch of Ritonavir raw materials, an antiviral drug primarily used for treating AIDS and also utilized during the COVID-19 pandemic [4] - Hengrui Medicine's subsidiary has received a clinical trial approval notice for the injectable HRS8179 drug, aimed at preventing severe brain edema after large-scale cerebral infarction. The project has seen a cumulative R&D investment of approximately 47.4 million yuan [5] Financial Reports - Sino Medical anticipates a 296.54% year-on-year increase in net profit for the first half of 2025, with expected revenue of 240 million yuan, reflecting a 12.53% growth [7] - WuXi Biologics forecasts a revenue growth of about 16% for the first half of the year, with profits expected to increase by approximately 54% and 56% for the company and its equity shareholders, respectively [8] Capital Markets - Lianhuan Pharmaceutical plans to issue up to 500 million yuan in technology innovation bonds to enhance R&D capabilities and optimize its debt structure. The bonds will be publicly issued with a term of no more than three years [10] Industry Developments - The NHSA has reported that over 100 drug varieties have applied to be included in the commercial health insurance innovative drug directory, which aims to incorporate high-value innovative drugs that cannot yet be included in the basic medical insurance directory [12] - As of the end of 2024, the cumulative recovery of medical insurance funds has reached 104.5 billion yuan, with a total balance of 3.86 trillion yuan in the insurance fund [14]

Group 1 - Valiant Biotech-B's dark market saw a maximum increase of 134.28%, reflecting market recognition of its antibody drug development pipeline in oncology and autoimmune diseases [1] - The company has one core product and 13 other candidates, with 6 having successfully entered clinical stages [1] - Long-term value will depend on the commercialization capabilities of new drugs [1] Group 2 - Hengrui Medicine's subsidiary received approval for clinical trials of HRS-1893 tablets, a selective myosin inhibitor aimed at treating heart failure with preserved ejection fraction [2] - The project has accumulated R&D investment of approximately 60.67 million yuan [2] - If clinical trials proceed successfully, it could become the first drug in this unmet clinical need, enhancing the company's competitiveness [2] Group 3 - 3SBio announced the formal effectiveness of a licensing agreement with Pfizer for the global development and commercialization rights of the PD-1/VEGF bispecific antibody SSGJ-707, excluding mainland China [3] - The agreement includes a total option and exercise fee of up to 150 million USD [3] - This partnership allows 3SBio to leverage Pfizer's resources for accelerated project development and commercialization [3] Group 4 - Zhonghui Yuantong updated its prospectus, indicating that its core products have been commercialized, alongside 11 vaccines in development [4] - The company has raised a total of 999.5 million yuan through three rounds of financing from notable investors [4] - The upcoming Hong Kong listing is expected to accelerate R&D and market expansion in the vaccine sector [4] Group 5 - Eddingpharm received approval for the registration and commercialization of multi-dose diquafosol sodium eye drops in China, which contains 3% diquafosol sodium [5] - The product is intended for the treatment of dry eye syndrome [5] - This approval enhances the treatment options for dry eye disease and is expected to contribute to the company's growth in the ophthalmic market [5]